Gut microbes may promote immune responses against colorectal cancer

September 6, 2017

Bacteria in the gut could stimulate tumor cells to produce factors that regulate cell mobility called chemokines that recruit T cells to the tumor, which is linked to improved outcomes, according to data presented at the Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, held Sept. 6-9.

"In the last decade it has become clear that the presence of certain types of immune cells, T cells in particular, within the tumor is associated with prolonged survival in patients with colorectal ," said Eleonora Cremonesi, PhD, a postdoctoral fellow in the group of Dr. G. Iezzi, at University of Basel, in Switzerland. "The factors promoting the recruitment of these immune cells and the mechanisms underlying their beneficial effect remain to be understood."

Cremonesi and team aimed to study the interaction between the and chemokines in promoting immune-cell infiltration into colorectal cancer and how this influences the clinical
course of the disease.

First, the team evaluated the expression of a series of genes encoding chemokines in a cohort of 62 freshly excised human colorectal cancers and adjacent healthy colonic tissue and identified gene signatures associated with the infiltration of immune cells into the colorectal cancers. They also evaluated the bacterial load in these tissues by assessing the expression of gene sequences exclusively expressed by bacteria.

Next, they analyzed the recruitment of immune cells in tumor tissues by injecting human colorectal cancer into the peritoneal cavity (etherotopic model) or in the gut (orthotopic model) of mice. While tumors developing in the are not exposed to the , those developing in the gut wall are, explained Cremonesi.

"We observed that in mice with orthotopic tumors exposed to the gut flora, the production of chemokines as well as the migration ability of human T lymphocytes derived from colorectal cancer specimens was significantly increased, compared with mice with etherotopic tumors that are not exposed to gut flora," she said. "These data suggest that the presence of the promote cytotoxic T-cell infiltration in tumors."

To further confirm their findings, the researchers treated the mice bearing orthotopic tumors with antibiotics and showed that it dramatically reduced the bacterial load. They also observed that the expression of genes encoding the chemokines involved in the recruitment of beneficial T-cell subset was significantly reduced. "These findings pave the way for additional studies aimed at the identification of bacterial strains of particular relevance in the induction of the production of these chemokines," Cremonesi said.

"That gut microbes play a role in colorectal cancer progression might appear like the Columbus egg. However, mechanisms involved in the generation of the peculiar microenvironment of
colorectal cancer and in the interaction between cancer and are still largely unclear," she added. "Our findings may open the way toward the development of new treatments aimed at modifying the gut flora to promote the infiltration of by lymphocytes displaying anti-tumor effects."

A limitation of the study is that the researchers could not assess the potential impact of the identified chemokines on patients' survival in their cohort, which is usually evaluated after five years, Cremonesi said. She expects this analysis to be part of follow-up studies.

Explore further: Bacterium actively drives colorectal cancer tumor cell growth

Related Stories

Bacterium actively drives colorectal cancer tumor cell growth

July 13, 2017
A subspecies of the bacterium Streptococcus gallolyticus appears to actively promote the development of colorectal cancer, according to new research published in PLOS Pathogens.

ONC201 may inhibit cancer stem cell self-renewals by altering their gene expression

August 2, 2017
ONC201 may inhibit cancer stem cell self-renewals by altering their gene expression, according to a study published August 2, 2017 in the open-access journal PLOS ONE by Varun Vijay Prabhu from Oncoceutics, Inc., USA and ...

Colorectal tumors initiate VEGF-A/CXCL1 cascade, creating distant niches for metastases

May 9, 2017
Primary colorectal tumors secrete VEGF-A, inducing CXCL1 and CXCR2-positive myeloid-derived suppressor cell (MDSC) recruitment at distant sites and establishing niches for future metastases, report Medical University of South ...

Researchers publish new findings on influence of high-fat diet on colorectal cancer

July 6, 2017
Poor diet is associated with 80% of colorectal cancer cases, but the exact pathways by which diet leads to cancer are not known.

Immunosuppression underlies resistance to anti-angiogenic therapy

July 14, 2017
A Massachusetts General Hospital (MGH) research team has identified a novel mechanism behind resistance to angiogenesis inhibitors - drugs that fight cancer by suppressing the formation of new blood vessels. In their report ...

Single-cell analysis reveals subtypes of colorectal tumors

March 20, 2017
Combining single-cell genomics and computational techniques, a research team including Paul Robson, Ph.D., director of single-cell biology at The Jackson Laboratory (JAX), has defined cell-type composition of cancerous cells ...

Recommended for you

Brain powered: Increased physical activity among breast cancer survivors boosts cognition

September 19, 2017
It is estimated that up to 75 percent of breast cancer survivors experience problems with cognitive difficulties following treatments, perhaps lasting years. Currently, few science-based options are available to help. In ...

Targeted antibiotic use may help cure chronic myeloid leukaemia

September 19, 2017
The antibiotic tigecycline, when used in combination with current treatment, may hold the key to eradicating chronic myeloid leukaemia (CML) cells, according to new research.

Researchers compose guidelines for handling CAR T cell side effects

September 19, 2017
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge for oncologists, one addressed by a team led by clinicians at The University ...

Bone marrow protein a 'magnet' for passing prostate cancer cells

September 19, 2017
Scientists at the University of York have shown that a protein in the bone marrow acts like a 'magnetic docking station' for prostate cancer cells, helping them grow and spread outside of the prostate.

Brain cancer breakthrough could provide better treatment

September 19, 2017
A new discovery about the most common type of childhood brain cancer could transform treatment for young patients by enabling doctors to give the most effective therapies.

A new paradigm for treating transcription factor-driven cancers

September 18, 2017
In the current issue of Proceedings of the National Academy of Sciences, researchers from Nationwide Children's Hospital describe a new paradigm for treating transcription factor-driven cancers. The study focuses on Ewing ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.